Table 1.
Baseline demographics and clinical characteristics of the study patients.
| Characteristics | Value (n = 65) % |
|---|---|
| Age median (mean ± SD) | 69.4 (21-95) |
| Gender n (%) | |
| Female | 24 (36.9%) |
| Male | 41 (63.1%) |
| Comorbidities no treatment for COVID-19*n (%) | |
| Diabetes | 10 (15.3%) |
| Hypertension | 3 (4.6%) |
| Chronic Kidney disease | 5 (7.7%) |
| COPD | 5 (7.7%) |
| Heart disease | 14 (21.5%) |
| Chronic neurological disease | 4 (6.1%) |
| Any medical immunosuppression | 3 (4.6%) |
| Symptom duration before admission, n (%) | |
| Fever | 29 (44.6%) |
| Cough/shortness of breath | 58 (89.2%) |
| Muscular or joint pain | 27 (41.5%) |
| Nausea and vomiting | 8 (12.3%) |
| Anorexia | 20 (30.7%) |
| Headache | 5 (7.7%) |
| Radiology no treatment for COVID-19 | |
| Ground-glass opacity (GGO) | 53 (81.5%) |
| Consolidation | 8 (12.3%) |
| Mix | 6 (9.2%) |
| COVID‐19 treatment | |
| Hydroxychloroquine | 25 (38.4%) |
| Oseltamivir | 3 (4.6%) |
| Kaletra | 2 (3%) |
| Outcomes | |
| Mechanical ventilation | 40 (61.5%) |
| ICU length of stay (days) | 17 (4-61) |
| Hospitalization duration | 22 (4-64) |
| In-hospital mortality | 54 (83.1%) |
| Discharged | 11 (16.9%) |
*As defined by clinicians in admission records.